All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
More information on our cookie policy.
BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Artificial intelligence
Coronavirus
Diagnosing and tracking COVID-19
Drugs to Watch 2020
The next pandemic
Premium reports
BioWorld Financings Reports
Disease Forecast Reports
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, February 27, 2021
See today's BioWorld Asia
Home
» Pharmaengine inks partnership with Sentinel Oncology for checkpoint kinase 1 inhibitor SOL-578
To read the full story,
subscribe
or
sign in
.
Pharmaengine inks partnership with Sentinel Oncology for checkpoint kinase 1 inhibitor SOL-578
Dec. 15, 2020
By
Gina Lee
No Comments
HONG KONG – Pharmaengine Inc. has signed a collaboration and licensing deal with Sentinel Oncology Ltd. for SOL-578.
BioWorld Asia
Deals and M&A
Cancer
Asia-Pacific